Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALFQ (U.S. Army Medical Research and Development Command)
- Development stage
- Unknown
- Lead developer
- U.S. Army Medical Research and Development Command
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
ALFQ (Army Liposome Formulation with QS-21) is a potent liposome-based vaccine adjuvant developed by the Walter Reed Army Institute of Research (WRAIR) and the U.S. Army Medical Research and Development Command. It is a next-generation formulation of the Army Liposome Formulation (ALF) that incorporates two powerful immunostimulants: synthetic monophosphoryl lipid A (specifically 3D-PHAD), which acts as a Toll-like receptor 4 (TLR4) agonist, and the saponin QS-21. These components are embedded within a phospholipid bilayer typically composed of DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine) and DMPG (1,2-dimyristoyl-sn-glycero-3-phospho-rac-glycerol), along with cholesterol. ALFQ is designed to elicit robust and balanced immune responses, including high antibody titers and strong Th1-biased cellular immunity. It has been evaluated in clinical trials for various infectious diseases, including HIV-1, malaria, and COVID-19, often as part of candidate vaccines to optimize immunogenicity and safety.
- Other names
- Army Liposome Formulation with QS-21
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on ALFQ (U.S. Army Medical Research and Development Command).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALFQ (U.S. Army Medical Research and Development Command).